Accutar Biotechnology Inc.
Records under this name other than the patents Accutar Biotechnology Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Back to Accutar Biotechnology Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,312,959 | Antisense oligonucleotides and their use for treating Pendred syndrome Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,168,058 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,195,459 | Glutarimide-Containing Pan-Kras-Mutant Degrader Compounds and Uses Thereof Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,110,291 | Glutarimide-Containing Pan-Kras-Mutant Degrader Compounds and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,420,956 | Novel Ureas Having Androgen Receptor Degradation Activity and Uses Thereof Lapsed on the fee record Ended Aug 23, 2026 · High confidence | Lapsed on the fee record | Ended Aug 23, 2026 | High confidence |
| US 11,312,702 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof Lapsed on the fee record Ended Apr 26, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 26, 2026 | USPTO record |
| US 9,944,632 | Compounds having estrogen receptor alpha degradation activity and uses thereof Lapsed on the fee record Ended Apr 17, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 17, 2026 | USPTO record |
| US 11,220,490 | Novel Ureas Having Androgen Receptor Degradation Activity and Uses Thereof Lapsed on the fee record Ended Jan 11, 2026 · High confidence | Lapsed on the fee record | Ended Jan 11, 2026 | High confidence |
| US 11,117,885 | Compounds having estrogen receptor alpha degradation activity and uses thereof Lapsed on the fee record Ended Sep 14, 2025 · USPTO record | Lapsed on the fee record | Ended Sep 14, 2025 | USPTO record |
| US 10,968,212 | Compounds having estrogen receptor alpha degradation activity and uses thereof Lapsed on the fee record Ended Apr 6, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 6, 2025 | USPTO record |